All patients
Age < 65y (younger) Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), nivolumab plus ipilimumab vs. platinum-based chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.79 [0.65; 0.96]
0.79 [0.65 ; 0.96 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 793 NA not evaluable progression or deaths (PFS)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.82 [0.69; 0.97]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.58 [0.41; 0.82]
0.71 [0.51 ; 1.00 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 68% 1,092 moderate not evaluable objective responses (ORR)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.31 [0.97; 1.76]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.26 [1.39; 3.66]
1.66 [0.97 ; 2.82 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 72% 1,092 moderate not evaluable STRAE (any grade)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.96 [1.36; 2.83]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.67 [1.51; 4.74]
2.15 [1.58 ; 2.92 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.98 [1.32; 2.98]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.19 [1.14; 4.20]
2.04 [1.44 ; 2.88 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable TRAE (any grade)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.66 [0.46; 0.94]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.28 [0.71; 2.30]
0.88 [0.46 ; 1.67 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 71% 1,072 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.96 [0.72; 1.29]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.02 [0.64; 1.65]
0.98 [0.76 ; 1.26 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.28; 3.45]
0.99 [0.28 ; 3.45 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.13 [1.95; 5.03]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 3.49 [1.78; 6.83]
3.25 [2.20 ; 4.78 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 5.13 [2.63; 10.00]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.90 [1.32; 6.37]
4.01 [2.31 ; 6.97 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 15% 1,072 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.11 [0.04; 0.28]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.26 [0.07; 0.92]
0.15 [0.07 ; 0.33 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 9% 1,072 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.24 [0.33; 4.65]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.23; 5.95]
1.22 [0.44 ; 3.39 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.02; 50.01]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.59 [0.02; 17.65]
0.73 [0.06 ; 9.60 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.25; 3.99]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62]
0.70 [0.21 ; 2.26 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.00 [0.60; 14.96]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.78 [0.29; 10.84]
2.38 [0.72 ; 7.91 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 2.00 [0.60; 6.70]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62]
0.96 [0.15 ; 6.03 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 56% 1,072 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.02; 59.79]
1.18 [0.02 ; 59.79 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.28 [0.06; 1.35]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.16; 8.49]
0.51 [0.13 ; 2.03 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 20% 1,072 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.01 [0.00; 0.23]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.03 [0.00; 0.46]
0.02 [0.00 ; 0.14 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.97 [0.18; 88.42]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 4.77 [0.21; 106.62]
4.35 [0.48 ; 39.10 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 18.21 [1.05; 315.26]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 7.20 [0.36; 145.12]
11.73 [1.48 ; 92.76 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.10 [0.01; 0.76]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.19 [0.02; 1.60]
0.13 [0.03 ; 0.59 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2 0% 1,072 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-29 21:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 416,864
